Form 4: Director Sells TOI Shares

The Oncology Institute Director Brad Hively sold 20,221 shares of common stock for $4.06 per share.

Summary

• Brad Hively, a Director of The Oncology Institute, Inc. (TOI), sold 20,221 shares of common stock.
• The transaction occurred on August 19, 2025, at a price of $4.06 per share.
• Following this sale, Brad Hively directly owns 622,980 shares of The Oncology Institute's common stock.

Sentiment

Score: 3

Explanation: The sale of 20,221 shares by a director, Brad Hively, suggests a potentially negative outlook from an insider perspective, which can be interpreted by the market as a bearish signal.

Negatives

• A Director, Brad Hively, sold a significant number of shares (20,221), which could be interpreted by the market as a lack of confidence in the company's near-term prospects or that the stock is fully valued at the current price.
• The sale price of $4.06 per share indicates the value at which the insider chose to divest, potentially setting a benchmark for market perception.

Future Outlook

NA

Industry Context

Insider sales, especially by directors, are closely watched in the healthcare sector as they can signal management's perception of future performance or valuation, potentially influencing investor sentiment regarding The Oncology Institute and its peers.

Comparison to Industry Standards

• This filing reports an individual insider transaction and does not provide company-wide financial or operational results that can be directly compared to industry benchmarks or specific comparable companies/projects. The significance of this sale is primarily in the context of insider sentiment rather than operational performance.

Related Party Transactions

• The sale of 20,221 shares of common stock by Brad Hively, a Director of The Oncology Institute, Inc., constitutes a related party transaction as it involves an insider of the company.

Stakeholder Impact

• Shareholders: May interpret the director's sale as a negative signal, potentially leading to decreased confidence and downward pressure on the stock price.
• Employees: No direct impact mentioned, but a declining stock price could affect morale or equity-based compensation.
• Customers/Suppliers/Creditors: No direct impact.

Key Dates

Recommendation

The sale of shares by a director, especially a significant amount, often signals a lack of confidence in the company's future prospects or that the stock is currently overvalued. This insider selling activity could lead to negative market sentiment and potential downward pressure on the stock price, suggesting a "sell" recommendation for investors.

Keywords

The Oncology Institute, TOI, Brad Hively, insider trading, Form 4, stock sale, director, common stock, healthcare, oncology